focus -WSS

focus

author：hotspot 2025-10-01 15:28:06 - browse：7

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Bird flu outbreak in cows is latest avian flu curveball

focus

knowledge

WSS

With competition flaring, obesity drug hits goal in liver disease study

More tobacco lobbyists active in statehouses

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Why palliative psychiatry is worth discussing

New documents shed light on MD Anderson Cancer Institute feud

hotspot

focus

explore

Supreme Court strikes down use of affirmative action

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Hepatitis C has a cure — but many Americans still lack access to it

PBM reform efforts get punted in Congress

Walensky prepares to leave CDC — and Congress — behind

FTC falls short on scrutinizing hospital mergers, study says

Medical records are filled with copy

Community Health Systems hospitals under DOJ investigation

Psychedelics group wrestles with new pharma identity

Bird flu in milk supply is likely coming from asymptomatic cows

focus

Q&A: Jennifer Adair on making gene therapy available globally

Cue Health's Covid

The Harvard botanist who searched for psychedelics in the Amazon

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Exact Sciences stock tumbles despite strong cancer detection sales

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

focus

focus

knowledge

explore